At the J.P. Morgan Healthcare Conference 2026, Roche Pharma’s CEO, Teresa Graham, shared the company’s vision for the next few years. Key priorities outlined by Graham include maximising the on-market portfolio to sustain growth until 2028, delivering key launches to support momentum, and preparing wide entry into novel disease areas (Alzheimer’s, obesity) via new molecular entities (NMEs) with a broad and diversified pipeline.
The company is on track to achieve its 2025 financial goal, with YTD sales by September 2025 reaching CHF 35.6bn ($44.5 bn), CHF 18bn ($22.5bn) coming from its oncology and haematology portfolio. The currently marketed portfolio continues to grow and progress with 17 blockbuster drugs. In oncology/haematology, areas of strength are in breast cancer (Phesgo, Kadcyla, Perjeta, Itovebi), solid tumors (Tecentriq), diffuse large B-cell lymphoma (DLBCL) (Polivy, Columvi/Lunsumio), and haemophilia A (Hemlibra).
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Graham noted that Roche builds and accelerates its pipeline through partnering and acquisitions. For about 60% of Roche’s R&D pipeline and total drug sales, the company has a partnership. Filing of up to three NMEs is anticipated in 2026. In the oncology pipeline, the limelight is on giredestrant, a next-generation selective oestrogen receptor degrader (SERD), currently in Phase III for early and metastatic breast cancer (mBC). Giredestrant + everolimus is in the pre-registration stage with the US Food and Drug Administration (FDA); the European Medicines Agency (EMA) filing is expected in 2026.
Giredestrant could replace standard-of-care endocrine therapy in oestrogen receptor (ER)-positive breast cancer and can be combined synergistically with PI3K/AKT/mTOR pathway inhibitors. Giredestrant is complemented by a portfolio of potentially best-in-class small molecules targeting key signalling nodes, including a PI3K inhibitor (Itovebi), a CDK4/2 inhibitor (GDC-4198) that could address a key mechanism of resistance to CDK4/6i, and a brain-penetrant HER2-tyrosine kinase inhibitor (ZN-1041). Clinical readouts for Phase III trials of giredestrant + palbociblib (1L ER+/HER2- mBC, persevERA) and Itovebi with fulvestrant (post CDKi hormone receptor (HR)+ mBC, INAVO121) and with Phesgo (PIK3CA-mut HER2+ mBC, INAVO122), are expected in 2026.
According to GlobalData analyst consensus forecast, giredestrant could reach $1.7bn in sales in 2031. The field of oral SERDs is highly competitive. AstraZeneca‘s camizestrant is in the pre-registration stage with the FDA and is expected to reach $1.8bn; palazestrant (Olema Pharmaceuticals) is currently in Phase III and is projected to gain $1.3bn in 2031. Clinical differentiation and in-house combinations are crucial to secure a leading position in the evolving HER2-/HR+ space.
Other key regulatory decisions expected in 2026 include the US approval of the Lunsumio + Polivy combination in DLBCL. Noteworthy clinical readouts in 2026 are Phase III trials for the KRAS G12C inhibitor divarasib in non-small cell lung cancer (KRASCENDO 1) and the Lunsumio label expansion into earlier treatment lines in follicular lymphoma (CELESTIMO).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the haemophilia A space, Graham noted NXT007 as a blockbuster-potential asset. NXT007 is a Phase II anti-coagulation factor IX and factor X bispecific antibody, licensed from Chugai Pharmaceutical. GlobalData’s analyst consensus forecast projects NXT007 sales to reach $760m in 2031.
Graham projected confidence in the ability of Roche’s portfolio of marketed products to deliver growth until 2028, strong momentum with upcoming 2026 launches and positive Phase III readouts, and the pipeline of potentially first-in-class/best-in-class medicines across oncology, haematology, immunology, neurology, and ophthalmology. In addition, Roche aims for a top-three player position in the obesity space with five NMEs planned for 2026 in a continued iteration of the incretin pathway and exploring novel mechanisms of action.
Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare conference 2026. Sign up here to receive a comprehensive report after the conference.
